While pharmacy benefit managers are watching cable, patients are streaming Netflix

The core mismatch: healthcare still rewards gatekeepers, patients reward convenience

PBMs sit in the middle of the prescription drug supply chain. In theory, they help insurers and employers manage pharmacy benefits, negotiate rebates, build formularies, contract with pharmacies, and control costs. In practice, critics across the policy spectrum increasingly argue that the system has become too concentrated, too vertically integrated, and too comfortable with opacity. When middlemen become more powerful than the people they are supposedly serving, the market starts to feel less like a service and more like an obstacle course.

And patients notice. They may not know every acronym floating around the drug-pricing debate, but they know what it feels like to leave a doctor’s office with a prescription and no confidence that the drug will be covered, affordable, or available at the pharmacy they actually use. They know what it feels like to be told a drug is “preferred,” “nonpreferred,” “step therapy required,” or “specialty only,” as if they accidentally signed up for a premium channel bundle instead of treatment for a chronic condition.

That disconnect matters because modern healthcare consumers are not comparing their pharmacy experience only to other healthcare experiences. They are comparing it to every digital experience they have. They are comparing it to same-day delivery, ride-sharing maps, streaming subscriptions, automatic payments, and apps that explain things in plain English. Healthcare does not get a pass simply because it is complicated. In the patient’s mind, complicated is exactly what a good system is supposed to simplify.

Why PBMs feel like cable

They thrive on bundles, black boxes, and fine print

The old cable model was simple in the worst possible way: you paid for a giant bundle, nobody could clearly explain the pricing, and every answer somehow produced three new fees. PBMs often create a similar feeling. Drug coverage can hinge on negotiated rebates, benefit design, utilization controls, spread pricing, specialty pharmacy steering, and network rules that are largely invisible to the patient at the moment they need care. By the time the patient sees the result, the real decision has already been made somewhere upstream.

That is why the most maddening phrase in healthcare is often not “denied,” but “covered with conditions.” Covered where? At what price? After how many appeals? Through which pharmacy? Only after trying what first? If your drug benefit works like a locked bonus feature, patients do not experience it as a benefit. They experience it as bureaucracy with branding.

The market got concentrated, then vertically integrated

Another reason the cable analogy lands: a small number of powerful players can shape what people see and how they get it. The modern PBM market has become highly concentrated, and that concentration is reinforced by ownership ties among insurers, PBMs, mail-order operations, and specialty pharmacies. When the same corporate family helps design the benefit, manage the utilization rules, and steer the fulfillment channel, it is fair to ask whether the system is optimizing for the sponsor, the patient, or the parent company.

That structure can create conflicts that are not always obvious on paper but are very obvious in lived experience. A patient may be nudged away from a local pharmacy toward an affiliated mail-order or specialty pharmacy. A lower-cost competitor may not get the best formulary placement if rebate economics point elsewhere. A plan sponsor may believe it is buying aggressive cost management, while the patient experiences only delayed access and confusing cost-sharing.

Prior authorization is the hold music nobody asked for

If PBMs are the cable bundle, prior authorization is the endless customer-service transfer. It is the part where a patient learns that “your doctor prescribed it” and “you can start it today” are not, in fact, the same thing. Physicians have been warning for years that prior authorization delays care, increases administrative burden, and can produce real harm. Patients do not need a policy brief to understand this. They feel it every time treatment becomes a paperwork relay race.

And that relay race is especially absurd in a digital-first era. We can stream a movie in six seconds, transfer money instantly, and track a package in real time down to the block. Yet a medication approval can still vanish into a black hole of faxes, phone trees, and portal ping-pong. That is not “care management.” That is a compatibility issue between a twentieth-century workflow and a twenty-first-century patient.

Why patients think like streamers now

Convenience is no longer a perk. It is the baseline.

Patients have changed. They book online, refill online, message providers online, and increasingly expect care to meet them where they are. The growth of telehealth, digital monitoring, mobile health tools, and app-based communication has trained consumers to expect convenience, speed, and visibility. They are not asking for healthcare to become entertainment. They are asking healthcare to stop acting shocked that convenience matters.

That expectation crosses age groups, but it is especially visible among younger adults who are more willing to switch providers or platforms when access feels clunky. They want fewer friction points, not more. They want better information before they show up, not after a denial letter arrives. They want a system that remembers them, explains itself, and lets them act without calling three numbers and repeating their date of birth like they are auditioning for a very boring game show.

People expect clarity, not scavenger hunts

The streaming-era mindset is not just about speed. It is about intuitive design. Patients want to know: Is the drug covered? What will it cost me today? Is there a lower-cost alternative? Can I get it at my regular pharmacy? If not, why not? How long will approval take? Those are not radical questions. They are the healthcare equivalent of asking whether the movie is available, what the subscription costs, and whether your device supports playback.

When those answers are hidden, delayed, or inconsistent, trust erodes. Patients begin to assume the system is built to confuse them, and to be honest, the system does not always rush in with evidence to the contrary. Surprise costs, shifting formularies, and last-minute coverage changes turn healthcare into a scavenger hunt. That may be acceptable for finding a hidden menu item at a trendy coffee shop. It is a terrible way to manage insulin, cancer therapy, asthma treatment, or rheumatoid arthritis medication.

The pharmacy experience is now part of the brand experience

For years, health plans treated pharmacy benefits as a technical backend function. Patients do not. To them, the drug experience is the brand experience. It shapes whether they trust the insurer, the employer-sponsored benefit, the pharmacy, and sometimes even the physician who wrote the prescription. If the prescription journey feels confusing, punitive, or unstable, the whole care journey feels broken.

That is why the patient side of the equation matters so much. Modern consumers increasingly judge institutions not just by what they promise, but by how easy they are to use. A beautifully marketed health plan with a maddening pharmacy benefit is basically a slick app with buffering problems. The logo may be polished. The experience still stinks.

What this mismatch looks like in the real world

For a patient with a chronic illness, the cable-era PBM model can turn maintenance into uncertainty. The drug that worked last month may require a new authorization this month. The neighborhood pharmacy that knows the patient’s history may suddenly be “out of network” for a specialty medication. A rebate-driven formulary decision may make one drug look cheaper to the plan while leaving the patient exposed to higher out-of-pocket costs tied to list price or coinsurance.

For community pharmacies, especially independent and rural ones, the mismatch is just as sharp. Patients still want local trust, human counseling, and access close to home. But many smaller pharmacies operate under reimbursement pressure and contract terms they say are increasingly difficult to survive. When a local pharmacy disappears, patients do not lose only a storefront. They lose a medication coach, a vaccine site, a troubleshooting desk, and often the most accessible clinician in the neighborhood.

For plan sponsors and employers, the problem is subtler but just as important. Many buy PBM services because they want value, purchasing leverage, and lower net spending. Fair enough. But if the savings are hard to verify, the workflows create delays, and employees experience the benefit as confusing or hostile, then the plan is not only a financial instrument. It is a workforce experience problem. Healthcare frustration eventually shows up as absenteeism, poor adherence, lower trust, and higher downstream costs.

What a streaming-era pharmacy benefit would actually look like

Transparent pricing at the point of care

A modern system should tell patients, in plain language and before the pickup counter showdown, what a medication will cost and why. Not after adjudication. Not after the denial. Not after the patient has already mentally committed to treatment. Real transparency means showing net patient-relevant cost, affordable alternatives, and expected changes before the prescription becomes a crisis.

Real-time authorization, not fax-era rituals

If prior authorization is going to exist, it should operate in real time whenever possible, integrate with clinical systems, and produce fast, trackable responses. A streaming-era benefit does not ask clinicians and patients to cosplay as document couriers. It uses interoperable data, standardized workflows, and clear rules. If a system can deny a drug with algorithmic confidence, it can at least explain the reasoning with digital competence.

Pharmacy choice that feels like choice

Patients should not be nudged into corporate maze routes when a clinically appropriate, local option is available. A healthier model would preserve network standards without using them as a pretext for steering patients into affiliated channels whenever the economics look attractive. Convenience should mean the pharmacy that works for the patient, not merely the one that best fits a vertical integration chart.

Benefit design aligned with adherence

The smartest drug benefit is not the one that looks cheapest on a spreadsheet in quarter one. It is the one that helps people actually start and stay on effective therapy. That means less reliance on list-price games, fewer abrupt formulary surprises, and more focus on affordability, continuity, and support. Patients do not become adherent because the PDF was excellent. They become adherent when the process is predictable.

Why reform feels inevitable now

The policy winds have shifted. Regulators, lawmakers, employers, physicians, pharmacists, and patient advocates increasingly agree on at least one point: the black-box version of pharmacy benefits is wearing thin. Even when stakeholders disagree on exactly how much PBMs contribute to total drug-spending problems versus manufacturer pricing, there is growing recognition that opacity, concentration, and misaligned incentives make the system harder to defend.

At the same time, patients are not getting less digital. They are getting more accustomed to frictionless experiences everywhere else. That means the reputational cost of outdated pharmacy benefit design will keep rising. Every denied refill, every unexplained pharmacy transfer, every mysteriously expensive copay, and every weeklong authorization delay now lands in a market where consumers know what well-designed systems feel like. The comparison is brutal, and PBMs are losing it.

In other words, this is not simply a compliance or reimbursement story anymore. It is a product-design story. And products that treat users like interruptions do not age well.

Patient-side experiences: what this feels like in real life

Imagine a patient leaving an appointment with what should feel like progress. The diagnosis is clearer. The treatment plan makes sense. The clinician is confident. For a brief, glorious moment, healthcare appears to be functioning as advertised. Then the prescription journey begins.

The first text from the pharmacy says the medication is delayed. The second says prior authorization is required. The third says the drug may need to go through a specialty pharmacy the patient has never heard of. The doctor’s office says they submitted the paperwork. The insurer says it is under review. The PBM says the preferred alternative must be tried first. Nobody is exactly wrong, but nobody is exactly useful either. The patient, who only wanted to start treatment, now has a part-time job in medical logistics.

This is where the title stops being clever and starts being painfully accurate. Patients do not experience this as “benefit management.” They experience it the way a streaming user would experience clicking play and being told to call customer support, swap devices, fax proof of residence, and maybe try season one of a different show first. In any other industry, that design would be laughed out of the market.

Talk to people who manage chronic conditions and a pattern emerges fast. They want reliability more than novelty. They want to know their refill will be there when the calendar says it should be there. They want their usual pharmacy to have enough information to help them. They want their out-of-pocket amount to feel like a number someone calculated, not a dare someone issued. They want to avoid treatment interruptions caused by benefit churn rather than clinical judgment.

Caregivers feel the strain too. Parents of children with asthma, diabetes, ADHD, or rare conditions often become full-time coordinators of approvals, formularies, refill timing, and appeals. Adult children helping aging parents learn quickly that the hardest part of a prescription is not always remembering to take it. Sometimes it is figuring out which version of the rules applies this month. The emotional cost is real. Administrative instability has a way of making illness feel bigger, louder, and more exhausting than it already is.

Even patients who are fairly tech-savvy can feel ambushed. They are comfortable using portals, apps, and telehealth. They will upload forms, check notifications, and compare pharmacy options. But they still hit the wall when the information is incomplete or contradictory. Digital access is only helpful when the digital experience is coherent. A sleek portal that cannot tell you why your medication was rejected is just a prettier version of confusion.

And then there is the quiet damage: abandonment. Some patients pay cash when they should not have to. Some postpone treatment until the next paycheck. Some accept an inferior alternative because the original medication is too difficult to access. Some simply give up. Not dramatically. Not with a press conference. Just a tired decision made on a Thursday afternoon after one too many phone calls.

That is the human side of the PBM debate. It is not only about rebates, spreads, or market structure. It is about whether the path from prescription to treatment feels humane. Right now, for too many people, it does not.

Conclusion

PBMs were built to manage drug benefits in an era that tolerated mystery, delay, and intermediary power as the price of doing business. Patients now live in a very different era. They expect clarity, convenience, control, and service that works without requiring detective work. That is the streaming mindset, and it is not going away.

So the real question is not whether patients are acting like consumers. They already are. The real question is whether pharmacy benefits can evolve fast enough to meet them there. If PBMs keep acting like cable, patients will keep feeling trapped in a package they never really chose. And in modern healthcare, that is no longer just frustrating. It is strategically unsustainable.